BRITISH PHARMACOPOEIA COMMISSION

EXPERT ADVISORY GROUP: MEDICINAL CHEMICALS 3

SUMMARY MINUTES

A meeting of Expert Advisory Group (EAG): Medicinal Chemicals 3 (MC3) was held at 10 South Colonnade, Canary Wharf, London E14 4PU on Tuesday 24th September 2019.

Present: Professor M Almond (*Chairman*), Mr J Beach (*vice-Chairman*), Dr J Beaman, Dr K Foster, Mr P Hampshire, Dr B Rackstraw, Dr R Torano, Mr I Williams.

In attendance: Mr A Evans, Miss H Ashraf, Dr H Bowden, Ms K Busuttil, Ms S Planou

Apologies: Mr C Goddard, Dr K Pugh

INTRODUCTORY REMARKS

The Chairman welcomed everyone to the meeting.

Declaration of interests Dr Beaman, Mr Hampshire and Dr Torano declared interests in one or more agenda items and appropriate action was taken.

Emergency evacuation procedure The emergency evacuation procedure for 10 South Colonnade was noted.

MHRA Update Dr Ian Hudson had retired from his position as Chief Executive Officer of the MHRA in September. Dr June Raine, the former Director of the Vigilance and Risk Management of Medicines Division, had been appointed as the interim CEO until a permanent replacement for Dr Hudson had been appointed.

I MINUTES MC3(19)32

The minutes and summary minutes of the meeting held on 26th February 2019 were confirmed.

II MATTERS ARISING FROM THE MINUTES MC3(19)33

The following matters arising were noted.

Acarbose Tablets **MC3(19)34**
The marketing authorisation holder had sent their new related substances methods and these were under evaluation in the Laboratory. The USP, JP, IP and ChP have been invited to participate in the monograph development process and will be provided with the Laboratory report upon completion.

Midazolam Oromucosal Solution **MC3(19)35**
Phytomenadione Preparations
Awaiting stability data from the MAH prior to revising limits

Diflucortolone Preparations **MC3(19)36**
This monograph will be published in BP2021.

Fluorescein Preparations **MC3(19)37**
A new related substance test was being investigated.

Future Laboratory investigations will be scheduled for: **MC3(19)38**

- Alprostadil preparations
- Norethisterone & ethinylestradiol tablets
- Norgestimate & ethinylestradiol tablets
- Gestodene & ethinylestradiol tablets
- Clomifene Tablets
- Cytarabine Injection
- Folic Acid

In progress Laboratory reports: **MC3(19)39**

- Methadone preparations
- Acarbose Tablets

BP2021 **MC3(19)40**
8 new monographs and 12 significantly revised monographs that were the responsibility of EAG MC3 and had been published in the BP2020.

WORKSHOP: ONLINE BP AND CHANGE NOTIFICATIONS **MC3(19)41**

A Workshop to discuss the BP website and track changes from an industry and academic user viewpoint was undertaken.

III MONOGRAPHS FOR THE BP 2021

572 BETAMETHASONE AND NEOMYCIN PREPARATIONS **MC3(19)42**
Betamethasone and Neomycin Ear Drops
Betamethasone and Neomycin Eye Drops
Betamethasone and Neomycin Nasal Drops

The draft monographs would be published in a future edition of the BP.

573 CALCIPOTRIOL AND BETAMETHASONE PREPARATIONS **MC3(19)43**
Calcipotriol and Betamethasone Cutaneous Foam
Calcipotriol and Betamethasone Gel
Calcipotriol and Betamethasone Ointment

The draft monograph would be published in a future edition of the BP.

574 DIFLUCORTOLONE PREPARATIONS **MC3(19)44**
Diflucortolone Cream
Diflucortolone Ointment
Diflucortolone Oily Cream

Monograph Titles There were three monographs for diflucortolone preparations, these were ointment, cream, and oily cream. The Secretariat had investigated if the monographs for cream and oily cream were required or if they could be consolidated into a single monograph. The Secretariat had found that these had been treated as separate entities by the regulator and by the BNF; given these findings it was concluded that the two separate monographs would be retained.

Assay The Laboratory had reported that there were difficulties in sourcing clocortolone hexanoate (internal standard) required to establish a replacement BPCRS. Members agreed that the requirement to use an internal standard was obsolete and could be deleted. The removal of the internal standard would remove the system suitability requirement and an alternate steroid that already exists in the BPCRS catalogue would be investigated as a replacement.

Members further agreed that the monographs should be added to the EAG Work programme to establish a related substances test.

575 MOMETASONE PREPARATIONS MC3(19)45

Mometasone Cream
Mometasone Ointment
Mometasone Scalp Application
Mometasone Inhalation Powder
Mometasone Aqueous Nasal Spray

The draft monographs would be published in a future edition of the BP.

576 DUTASTERIDE CAPSULES MC3(19)46

The draft monographs would be published in a future edition of the BP.

577 OXYCODONE PROLONGED-RELEASE TABLETS MC3(19)47

Production statement The Secretariat proposed to include a Production statement for the control of parenteral tamper (abuse) proof formulations in the monograph. The proposed text would require these formulations to comply with the quality attributes of the monograph whilst permitting different (in-house validated) sample preparation that were required to obtain solutions of these products for testing. It was noted that these products had been formulated to form gels when mixed with normal solvents to stop addicts from injecting oxycodone when they try to extract it from the tablet matrix.

578 LEVONORGESTREL TABLETS MC3(19)48

Dissolution The secretariat had been contacted by an MAH to amend the sample dilution step in the dissolution test. Members agreed that the diluent in the dilution requirement should be changed to match the dissolution medium.

579 FLUMETASONE AND CLIOQUINOL EAR DROPS **MC3(19)49**

Content A MAH had contacted the Secretariat to request the content (assay) limits were widened to 90.0 – 105.0%. Members agreed that further data showing the degradation of the API was required to ensure the product was understood over its shelf life.

580 ZUCLOPENTHIXOL ACETATE **MC3(19)50**

The members agreed the secretariat should include the BP 2016 requirements in the monograph for zuclopenthixol acetate (API).

581 PYRIDOXINE TABLETS **MC3(19)51**

Identification The old IR procedure was removed as it contained chloroform and a new solvent would require laboratory investigation. Members agreed that the IR procedure could be replaced by a combination of the current Identification B and a peak comparison requirement using the new Related substances test.

Dissolution Members agreed that the draft dissolution method was suitable with a run time of 45 minutes.

Related substances The method in the draft monograph was based on the MAH data which in turn used the Ph. Eur. API method as the basis for the their method development.

582 ALENDRONIC ACID AND COLECALCIFEROL TABLETS **MC3(19)52**

The draft monographs would be published in a future edition of the BP.

583 EXEMESTANE TABLETS **MC3(19)53**

The draft monographs would be published in a future edition of the BP.

V FOR INFORMATION

585 MC3 Work Programme **MC3(19)54**

A copy of the work programme for the EAG was provided for information. Members were asked to contribute data should they have interest in any of the products.

586 Out of Stock BPCRS **MC3(19)55**

The out of stock BPCRS that were used in the monographs the EAG was responsible for were noted. The Laboratory confirmed the dates these were due back in stock

EUROPEAN PHARMACOPOEIA **MC3(19)56**

see www.pharmacopoeia.com for European matters

VII AOB **MC3(19)57**

A source for the laboratory reagent nitroethane was requested.

VIII NEXT MEETING

25 February 2020